ZYMERGEN INC.

(ZY)
  Report
Real-time Estimate Cboe BZX  -  05/17 03:00:10 pm EDT
1.425 USD   -5.00%
05/12ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
05/12ZYMERGEN : Q1 Earnings Snapshot
AQ
05/12TRANSCRIPT : Zymergen Inc., Q1 2022 Earnings Call, May 12, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymergen Launches Drug Discovery Unit

01/10/2022 | 03:49am EDT


ę MT Newswires 2022
All news about ZYMERGEN INC.
05/12ZYMERGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/12ZYMERGEN : Q1 Earnings Snapshot
AQ
05/12TRANSCRIPT : Zymergen Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12Earnings Flash (ZY) ZYMERGEN Reports Q1 Revenue $4.8M, vs. Street Est of $3.34M
MT
05/12Zymergen Reports Preliminary First Quarter 2022 Financial Results
AQ
05/12Zymergen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10TRANSCRIPT : Zymergen Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
04/29Zymergen to Participate in the BofA Securities 2022 Healthcare Conference
AQ
04/13Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022
AQ
04/13Goldman Sachs Adjusts Zymergen's Price Target to $4 from $6, Keeps Neutral Rating
MT
More news
Analyst Recommendations on ZYMERGEN INC.
More recommendations
Financials (USD)
Sales 2022 13,4 M - -
Net income 2022 -294 M - -
Net cash 2022 91,0 M - -
P/E ratio 2022 -0,51x
Yield 2022 -
Capitalization 155 M 155 M -
EV / Sales 2022 4,75x
EV / Sales 2023 5,10x
Nbr of Employees 505
Free-Float 92,5%
Chart ZYMERGEN INC.
Duration : Period :
Zymergen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMERGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 1,50 $
Average target price 3,38 $
Spread / Average Target 125%
EPS Revisions
Managers and Directors
Jay T. Flatley Chairman & Chief Executive Officer
Enakshi Singh Chief Financial Officer
Zachariah Serber Director & Chief Science Officer
Rohit Sharma Independent Director
Matthew Ocko Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZYMERGEN INC.-77.58%155
SHIN-ETSU CHEMICAL CO., LTD-9.81%57 803
BASF SE-20.21%46 334
DUPONT DE NEMOURS, INC.-20.61%32 612
SASOL LIMITED53.41%15 415
FMC CORPORATION6.49%14 737